B Lynne Parshall has sold stock and made no open-market buys since Jan 2016

B. Lynne Parshall is a biotechnology executive and corporate director who serves as a Director of Cytokinetics, Inc., where she chairs the Audit Committee and sits on the Nominating and Governance, Compliance, and Commercial Committees.( In this role she brings more than three decades of strategic, financial, operational, and governance experience to the company, including recent insider trading activity in June 2026 in which she sold 5,000 shares of Cytokinetics common stock, retaining 15,784 shares as direct holdings.(

Parshall’s career spans senior leadership positions and board roles across the life sciences sector. She has been a long‑standing director of Ionis Pharmaceuticals, Inc., previously serving as its Chief Operating Officer, Chief Financial Officer, Corporate Secretary, and in other executive roles since the early 1990s.( She is CEO of Lyme Pinnacle Consulting LLC, providing strategic advisory services to public and private biotechnology companies, and serves on the boards of several biopharmaceutical and life sciences companies including Foghorn Therapeutics, Repertoire Immune Medicines, Ring Therapeutics, Alltrna, and Celdara Medical.( Earlier in her career, Parshall practiced law as a partner at Cooley LLP, focusing on biotechnology clients, and she is a member of the American and California Bar Associations.( She holds an A.B. from Harvard University and a J.D. from Stanford University, and has earned NACD Directorship Certification, underscoring her expertise in corporate governance.(

Written by Perplexity from public sources.